Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (18)

2024

  1. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

2022

  1. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  2. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

    Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058

  3. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  4. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

2021

  1. Conocimientos, percepciones, actitud, barreras y facilitadores del uso de biosimilares entre médicos y farmacéuticos de hospital: Una encuesta española

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 45, Núm. 5, pp. 240-246

2020

  1. COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020)

    Gastroenterologia y Hepatologia, Vol. 43, Núm. 7, pp. 408-413

  2. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis

    Gastroenterologia y Hepatologia, Vol. 43, Núm. 2, pp. 97-105

2019

  1. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial

    Digestive and Liver Disease, Vol. 51, Núm. 4, pp. 529-535

2018

  1. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study

    American Journal of Gastroenterology, Vol. 113, Núm. 3, pp. 396-403

  2. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients

    Gastroenterologia y Hepatologia

2017

  1. Adalimumab vs azathioprine in the prevention of postoperative Crohn's disease recurrence. A GETECCU randomised trial

    Journal of Crohn's and Colitis, Vol. 11, Núm. 11, pp. 1293-1301

  2. Association between disease activity and quality of life in ulcerative colitis: Results from the CRONICA-UC study

    Journal of Gastroenterology and Hepatology (Australia), Vol. 32, Núm. 11, pp. 1818-1824

  3. Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

    American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131

2016

  1. Diagnostic performance of the simple clinical colitis activity index self-administered online at home by patients with ulcerative colitis: CRONICA-UC study

    American Journal of Gastroenterology, Vol. 111, Núm. 2, pp. 261-268

2014

  1. Disease severity in familial cases of IBD

    Journal of Crohn's and Colitis, Vol. 8, Núm. 3, pp. 234-239

  2. Risk of colectomy in patients with ulcerative colitis under thiopurine treatment

    Journal of Crohn's and Colitis, Vol. 8, Núm. 10, pp. 1287-1293

2012

  1. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: A case series

    European Journal of Gastroenterology and Hepatology, Vol. 24, Núm. 7, pp. 756-758